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Abstract
Background: A synovial sarcoma (SS) is an aggressive soft tissue tumor that classically occurs in the extremities
near, but rarely within large joints, in young adults. Variable symptoms and clinical manifestations may be
encountered and a definite diagnosis should depend on pathological results. This poses certain difficulties in
arriving at a prompt diagnosis and appropriate treatment.
Case presentation: We report the case of a 68-year-old woman patient who presented an inguinal mass with
swelling and pain in the right lower limb. She underwent surgery, and later received systematic intravenous
chemotherapy. The pathological studies, especially the specific chromosomal translocation of a t(X;18) (p11.2;q11.2),
confirmed the diagnosis as a synovial sarcoma. To the best of our knowledge, this is the first report of a
monophasic synovial sarcoma in the inguinal region.
Conclusion: Besides making the readership aware of the rarity of location and age of this present case, this report
distinctly highlights the great value of a molecular analysis of an SYT associated genetic alteration in the diagnosis
of synovial sarcoma occurring at rare sites especially when immunochemical results are equivocal.
Background
A synovial sarcoma (SS) is an aggressive soft tissue
tumor, which mainly occurs in the para-articular region
of extremities with a predilection of lower limb. It
usually develops in adolescents and young adults
between the age of 15 and 40 years [1-3]. The detection
of a reciprocal translocation between chromosomes X
and 18 t(X:18) has led to the identification of an SS18
gene(also known as SYT) rearrangement being involved
in the formation of a SYT-SSX fusion protein in syno-
vial sarcomas[4-6]. With the advent of immunohisto-
chemistry and molecular techniques, cases of synovial
sarcomas have been reported in unusual location
including the head and neck[7], mediastinum[8], lung
[9], abdominal wall[10], intraabdominal[11], kidney[12]
and retroperitoneum[13]. Isolated rare cases were men-
tioned in the vulva [14], skin [15], blood vessels [16]
and nerves [17].
Inguinal synovial sarcomas are rare findings with only
o n ec a s er e p o r ti nt h eE n g l i s hl i t e r a t u r e[ 1 8 ] .H e r ew e
report a case of an inguinal synovial sarcoma presented
with pain and swelling in the right lower limb.
Case report
A 68-year-old woman was admitted with a complaint of
swelling and pain in her right lower limb. She had felt a
progressive swelling and pain for more than two months
without any obvious cause. Subsequently, she was
referred to a vascular surgery clinic where a mass was
found in the right inguinal area by physical examination.
The mass was like a goose-egg in shape, hard, fixed and
couldn’t disappear under pressure. A Doppler ultrasonic
vessel examination suggested that there were small
blood clots and reduced blood flow in the veins of the
right lower limb. Correspondingly, CT and CT angiogra-
phy (CTA) scans were conducted which displayed a
mass in her right inguinal area with involvement of the
femoral vein (Figure 1, 2). The patient did not have any
family history. She had never smoked and had a normal
chest X- ray exam.
A surgical excision was performed which revealed a
tumor located in the right inguinal region with adhesion
to the right femoral vein and artery. The tumor was
completely resected with negative margin. Grossly, the
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surface was firm and white-to-tan. Microscopic appear-
ances were monomorphic, highly cellular composed of
plump, spindled cells growing in short fascicles. The
tumor cells had ovoid nuclei and minimal cytoplasm
with frequent mitotic activity and atypical nuclei (Figure
3). Immunohistochemically, the tumor cells were posi-
tive for the epithelial membrane antigen(EMA), calreti-
nin, cytokeratin(CK), vimentin (VIM), but negative for
smooth muscle actin(SMA), muscle specific actin(MSA),
CD117 and S100. The molecular analysis of the paraf-
fin-embedded neoplasm sample by fluorescence in situ
hybridization (FISH) revealed a SYT-SSX fusion tran-
script (Figure 4). Based on these findings, a primary
malignant synovial sarcoma was diagnosed while the
other most likely diagnosis of a sarcomatoid mesothe-
lioma was excluded.
For personal reasons, the patient refused to receive
any chemotherapy after the operation. Unfortunately,
lung and spleen metastasis were found 15 months after
o p e r a t i o ni nar o u t i n ep o s t o p e r a t i v ef o l l o w - u p .T h e
patient was referred to the oncology department where
she received systemic intravenous chemotherapy (ifosfa-
mide, doxorubicin and cisplatin). However, the patient
responded poorly to the treatment and finally died 9
months later due to an initially poor and subsequently
rapidly worsening condition.
Discussion
Synovial sarcomas are uncommon soft tissue tumors
accounting for 5-10% of the soft tissue sarcomas. They
usually develop in children and young adults and
approximately 95% of SSs occur in the extremities. They
Figure 1 Pre-operative CT scan showing a pelvis mass (M)
adjacent to the femoral artery (arrow) and femoral vein
(arrowhead).
Figure 2 Pre-operative CTA showing a pelvis mass (M) com-
pressing the right femoral artery (arrow) and especially the
femoral vein (arrowhead).
Figure 3 Histological section (haematoxylin and eosin, original
magnification: ×200). The tumor consisted of atypical spindle-
shaped cells, which arranged in fascicles.
Figure 4 FISH result shows a break-apart red and green signal
per nucleus in SS tumor cells (arrows), indicating the presence
of a t(X;18) translocation.
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lymph node [1].
Two major histologic subtypes exist: monophasic and
biphasic synovial sarcomas. The classical SS has a bipha-
sic appearance with a mixture of epithelial and spindle
cells in varying proportions. The monophasic SS con-
sisting solely of sarcomatous components is often diag-
nostically challenging. Synovial sarcomas typically occur
in patients between the age of 15 and 40 years, rarely in
the elderly. Patients common l yp r e s e n tw i t hap a l p a b l e
mass or swelling, associated with pain in almost half of
the patients. The most common sites include the lower
extremities (60%), with a special predilection for the
knee area; the upper extremities (23%); the head and
neck region (9%), particularly in the retropharyngeal and
parapharyngeal areas; and the trunk (8.1%), most com-
monly involving the abdominal wall or retroperitoneum
[1]. SSs occuring in the inguinal region are exceedingly
rare. In a retrospective revi e wo f2 0p a t i e n t s ,H u u b [ 1 9 ]
et al mentioned one SS case in the groin region but
with no detailed documentation. The only reported case
in the English literature is that of a 19-year-old Japanese
female patient with the classic biphasic form of SS[18].
No immunohistochemical or further pathological analy-
sis findings were mentioned in that brief report.
In our case, heavily stained nucleus, mitotic activity
and atypical spindle-shaped cells with an increase in
nucleus to cytoplasm ratio were observed under the
light microscope. A panel of immunohistochemical
staining was done for differential diagnosis. The spindle
cells were positive for epithelial membrane antigen
(EMA), calretinin, cytokeratin (CK), vimentin (VIM) and
proliferating cell nuclear antigen (PCNA), but negative
for smooth muscle actin(SMA), muscle specific actin
(MSA), CD117 and S100. These findings helped to
exclude the presence of a leiomyosarcoma, malignant
peripheral nerve sheath tumor(MPNST), gastrointestinal
stromal tumor(GIST). Despite of a panel of immunohis-
tochemical staining results, however, to distinguish
between sarcomatoid mesothelioma and synovial sar-
coma was extremely difficult because both types of
tumors share the same immunostaining results. They
show an overlap in their respective immumostaining
spectrum of EMA, calretinin, vimentin and S-100. To
date, there exist no ideal immunohistochemical markers
to reliably diagnose the SS and make an unequivocal
distinction. The gold standard applied in order to con-
firm the diagnosis of SS is to detect the specific t(X;18)
(p11.2;q11.2) translocation[4,20] at molecular level. The
t(X;18)(p11.2;q11.2) translocation is a cytogenetic hall-
mark of the SS and is present in more than 90% of the
cases[21]. The SS18-SSX fusions do not seem to occur
in other types of sarcomas. To determine whether the
SYT-SSX fusion transcript associated with t(X;18)
translocation is present, a dual-color break-apart fluor-
escence in situ hybridization (FISH) assay for SYT gene
disruption was performed in paraffin-embedded tumor
material, which showed a positive result. As the t(X;18)
translocation is unique to the SS, its identification pro-
vided the definite diagnosis for this case. We consider
this FISH assay described by Surace et al [22], a preferred
clinical method in the diagnosis, especially when suffi-
cient quality of RNA for PCR could not be extracted.
Apart from its diagnostic value, this translocation fusion
type was found to be the single most significant prognos-
tic factor by multivariate analysis in SS patients [23].
However, a European retrospective analysis found that
the most important factor in determining the prognosis
of these patients is histological grade, and not SYT-SSX
fusion type [24].
Surgery is the mainstay treatment. Chemotherapy and
radiation therapy should be considered as additional
treatment options or may be utilized in cases of relapse.
Prognosis is poor with local recurrence and metastases in
almost 50% of the patient [1]. Metastases occur mainly to
lungs as was the case for this patient. Since Ifosfamide
based chemotherapy has been shown to produce notable
responses in the treatment of metastatic SS [25], how-
ever, its effect on this patient was not satisfactory. Finally,
despite the surgery and chemotherapy she had received,
our patient has only survived for less than two and a half
years after her initial clinical presentation.
Currently, with known genetic alterations in SSs, new
therapies targeting DNA or protein are under investiga-
tion. Vaccine of SYT-SSX junction peptide was tested in
a pilot study [26]. Recent studies shows retinoic acid
and its derivatives could induce the differentiation of SS
cell lines and inhibit cell growth both in vitro and in
vivo [27]. However, the therapeutic efficacy is still under
evaluation.
In conclusion, this is the fir s tr e p o r to fam o n o p h a s i c
synovial sarcoma in the inguinal region. We report this
unusual case because of the tumor location and patient’s
old age. The case illustrates possible differential diag-
noses before the treatment. It also highlights the value
of molecular analysis in ascertaining the diagnosis of a
synovial sarcoma at a rare site, especially when immu-
nohistochemical results are equivocal.
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